Compare Gilead Sciences, Inc. (GILD) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tapestry, Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.6 (market cap $163.51B), while Tapestry, Inc. trades at $143.72 (market cap $28.34B). The key difference: Gilead Sciences, Inc. is far larger — about 5.8× Tapestry, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | TPR | |
|---|---|---|
Market Cap | $163.51B | $28.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $160.49 |
52-Week Low | $108.22 | $95.69 |
Enterprise Value | $178.05B | $31.19B |
Dividend Yield | 2.49% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
TPR stock trades at $143.67, up 6.14% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $7.01B in 2025 with net income of $183.20M, though margins compressed from prior years. Recent quarters show consistent earnings beats, and analyst sentiment remains strongly positive with a consensus price target of $184.14. Cash flow trends indicate volatility, with 2025 net cash flow negative $5.02B due to financing activities.
Outlook: Strong buy ratings and earnings momentum support upside potential, but elevated valuation ratios and technical bearishness pose near-term risks. Key opportunities include digital growth and brand strength, while risks involve margin pressure and high debt levels. Investors should weigh robust analyst confidence against fundamental headwinds for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
